

ABSTRACT OF THE DISCLOSURE

A compound selected from those of formula (I) :



wherein :

5 p represents an integer of from 0 to 6 inclusive,

n represents an integer of from 0 to 6 inclusive,

10 R<sub>1</sub>, and R<sub>2</sub> represent a group selected from hydrogen, alkyl, aryl and arylalkyl, or R<sub>1</sub>+R<sub>2</sub> form together with nitrogen carrying them saturated, monocyclic, or bicyclic system,

X represents a group selected from oxygen, sulphur, a group -CH=CH-, methylene, a group of formula -HC=N-O- and a group of formula -O-CH<sub>2</sub>-CH=CH-, in which groups oxygen is linked to Y of the compounds of formula (I),

15 Y represents a group selected from aryl, heteroaryl, arylalkyl, heteroarylalkyl, -C(O)-A, and -C(S)-A,

A represents a group selected from alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, and NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub>, and R<sub>4</sub> represent a group selected from hydrogen, alkyl, aryl, and arylalkyl, or R<sub>3</sub>+R<sub>4</sub> form together with nitrogen carrying them monocyclic, or bicyclic (C<sub>3</sub>-C<sub>10</sub>) system,

its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful as specific nicotinic ligands of α<sub>4</sub>β<sub>2</sub> receptors.